Your browser doesn't support javascript.
loading
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb, Antje; Herranz, Nicolás; Arce-Gallego, Sara; Miranda, Susana; Buroni, Lorenzo; Yuan, Wei; Athie, Alejandro; Casals, Teresa; Carmichael, Juliet; Rodrigues, Daniel Nava; Gurel, Bora; Rescigno, Pasquale; Rekowski, Jan; Welti, Jon; Riisnaes, Ruth; Gil, Veronica; Ning, Jian; Wagner, Verena; Casanova-Salas, Irene; Cordoba, Sarai; Castro, Natalia; Fenor de la Maza, Maria Dolores; Seed, George; Chandran, Khobe; Ferreira, Ana; Figueiredo, Ines; Bertan, Claudia; Bianchini, Diletta; Aversa, Caterina; Paschalis, Alec; Gonzalez, Macarena; Morales-Barrera, Rafael; Suarez, Cristina; Carles, Joan; Swain, Amanda; Sharp, Adam; Gil, Jesus; Serra, Violeta; Lord, Christopher; Carreira, Suzanne; Mateo, Joaquin; de Bono, Johann S.
Afiliação
  • Neeb A; The Institute of Cancer Research, London, UK.
  • Herranz N; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
  • Arce-Gallego S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
  • Miranda S; The Institute of Cancer Research, London, UK.
  • Buroni L; The Institute of Cancer Research, London, UK.
  • Yuan W; The Institute of Cancer Research, London, UK.
  • Athie A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Casals T; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Carmichael J; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Rodrigues DN; The Institute of Cancer Research, London, UK.
  • Gurel B; The Institute of Cancer Research, London, UK.
  • Rescigno P; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Rekowski J; The Institute of Cancer Research, London, UK.
  • Welti J; The Institute of Cancer Research, London, UK.
  • Riisnaes R; The Institute of Cancer Research, London, UK.
  • Gil V; The Institute of Cancer Research, London, UK.
  • Ning J; The Institute of Cancer Research, London, UK.
  • Wagner V; MRC London Institute of Medical Sciences (LMS) and Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College, London, UK.
  • Casanova-Salas I; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Cordoba S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Castro N; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fenor de la Maza MD; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Seed G; The Institute of Cancer Research, London, UK.
  • Chandran K; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Ferreira A; The Institute of Cancer Research, London, UK.
  • Figueiredo I; The Institute of Cancer Research, London, UK.
  • Bertan C; The Institute of Cancer Research, London, UK.
  • Bianchini D; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Aversa C; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Paschalis A; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Gonzalez M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Morales-Barrera R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Suarez C; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Carles J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Swain A; The Institute of Cancer Research, London, UK.
  • Sharp A; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Gil J; MRC London Institute of Medical Sciences (LMS) and Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College, London, UK.
  • Serra V; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
  • Lord C; The Institute of Cancer Research, London, UK.
  • Carreira S; The Institute of Cancer Research, London, UK.
  • Mateo J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: jmateo@vhio.net.
  • de Bono JS; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Johann.debono@icr.ac.uk.
Eur Urol ; 79(2): 200-211, 2021 02.
Article em En | MEDLINE | ID: mdl-33176972
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Mutadas de Ataxia Telangiectasia / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Mutadas de Ataxia Telangiectasia / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido